KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial.

Lichen Tang, Min He, Cuizhi Geng, Zhimin Fan, Rui Ling, Guangdong Qiao, Li Cai, Ting Luo, Feng Jin, Haibo Wang, Anqin Zhang, Hongwei Zhang, Xiaohua Zeng, Xiaojia Wang, Ming Jiang, Zhonghua Wang, Zhimin Shao

Oncologist 30(6) oyaf101

PMID40504550
PMCIDPMC12160816
DOI10.1093/oncolo/oyaf101
发表日期2025-06-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Pegylated liposomal doxorubicin (PLD) was shown to have comparable efficacy to doxorubicin, with significantly reduced cardiotoxicity. This study evaluated the cardiotoxicity and efficacy of the PLD-based regimen compared with those of the doxorubicin-based regimen as adjuvant therapy for early-stage breast cancer (BC). METHODS: In this open-label, randomized controlled trial, patients with early-stage BC were assigned to receive either 4 cycles of PLD (study group) or doxorubicin (control group) plus cyclophosphamide followed by 4 cycles of docetaxel/paclitaxel. The primary endpoint was cardiotoxicity. RESULTS: Between November 2017 and September 2019, 247 patients (study group, n = 131; control group, n = 116) were enrolled. Incidence rates of abnormal left ventricular ejection fraction (LVEF, 0 vs. 1.7%) and congestive heart failure (0.0% vs. 0.9%) were similar between the two groups (all P > 0.05). A lower proportion of elevated high-sensitivity cardiac troponin T (3.8% vs. 30.2%, P < 0.001) was observed in the study group. The 5-year disease-free survival (82.7% vs. 83.8%) and overall survival (90.4% vs. 91.6%) rates were comparable (all P > 0.05). Grade 3-4 adverse events in the study group were significantly less than in the control group (43.5% vs. 61.2%, P = 0.005). CONCLUSION: The PLD-based regimen for early-stage BC showed significantly lower rates of elevated hs-cTnT and grade 3-4 AEs with comparable efficacy to the doxorubicin-based regimen. (ClinicalTrials.gov Identifier: NCT03949634; IRB Approved: Ethics committee institutional review board of Shanghai Cancer Hospital, Fudan University's (No. 1706173-19-1904B) and other center).

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 4.

Kaplan-Meier curves. (A) 5-year DFS rate in the 2 groups. (B) 5-year OS rate in the 2 groups. Abbreviations: 95% CI, 95% confidence interval; DFS, disease-free survival; OS, overall survival.

A

DFS

Figure 4. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Figure 4. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:extreme jump
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Trial profile. Abbreviations: FAS, full analysis set; SS, safety analysis set.
非 KM Figure
Figure 2.Study design. Abbreviations: BC, breast cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; PLD, pegylated liposomal doxorubicin.
非 KM Figure
Figure 3.Changes in levels of LVEF and serum cardiac biomarkers during the treatment and follow-up. (A) LVEF. (B) CK. (C) CK-MB. (D) Hs-cTnT. (E) ProBNP. Abbreviations: C, cycle; CK, creatine kinase; CK-MB, CK-myocardial band; hs-cTnT, high-sensitivity cardiac troponin T; LVEF, left ventricular ejection fraction; M, month; proBNP, pro-brain natriuretic peptide; *, compared with baseline, P < .05; #, compared with the study group, P < .05.
非 KM Figure